References
- Suzman R, Beard J. Global health and aging. Available from: www.nia.nih.gov/sites/default/files/nia-who_report_booklet_oct-2011_a4__1-12-12_5.pdf
- McElhaney JE. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging health 2008;4(6):603-13
- Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ 2009;339:b4904
- Aspinall R, Lang PO. The Avalanche is coming. and just now it’s starting to snow. Front Immunol 2013;4:165
- Gautret P, Gaudart J, Leder K, et al. Travel-associated illness in older adults (>60 y). J Travel Med 2012;19(3):169-77
- Marti F, Steffen R, Mutsch M. Influenza vaccine: a travelers’ vaccine? Expert Rev Vaccines 2008;7(5):679-87
- Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008;451(7181):990-3
- Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001;344(24):1807-14
- Plotkin SA. Vaccines: past, present and future. Nat Med 2005;11(Suppl 4):S5-11
- Moxon ER, Siegrist CA. The next decade of vaccines: societal and scientific challenges. Lancet 2011;378(9788):348-59
- Moxon ER, Das P, Greenwood B, et al. A call to action for the new decade of vaccines. Lancet 2011;378(9788):298-302
- Nabel GJ. Designing tomorrow’s vaccines. N Engl J Med 2013;368(6):551-60
- Michel JP, Lang PO. Promoting life course vaccination. Rejuvenation Res 2011;14(1):75-81
- Dowdle WR, Cochi SL. The principles and feasibility of disease eradication. Vaccine 2011;29(Suppl 4):D70-3
- Lang PO, Govind S, Bokum AT, et al. Immune senescence and vaccination in the elderly. Curr Top Med Chem 2013;13(20):2541-50
- Shaw AC, Panda A, Joshi SR, et al. Dysregulation of human Toll-like receptor function in aging. Ageing Res Rev 2011;10(3):346-53
- Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010;184(5):2518-27
- Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002;168(11):5893-9
- Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011;121(8):3109-19
- Ademokun A, Wu YC, Martin V, et al. Vaccination-induced changes in human B-cell repertoire and pneumococcal IgM and IgA antibody at different ages. Aging Cell 2011;10(6):922-30
- Yager EJ, Ahmed M, Lanzer K, et al. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med 2008;205(3):711-23
- Aspinall R, Andrew D. Thymic atrophy in the mouse is a soluble problem of the thymic environment. Vaccine 2000;18(16):1629-37
- Buffa S, Bulati M, Pellicano M, et al. B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology 2011;12(5):473-83
- Sapey E, Greenwood H, Walton G, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood 2014;123(2):239-48
- Chidrawar SM, Khan N, Chan YL, et al. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing 2006;3:10
- Laurent M, Bastuji-Garin S, Plonquet A, et al. Interrelations of immunological parameters, nutrition, and healthcare-associated infections: Prospective study in elderly in-patients. Clin Nutr 2014. [Epub ahead of print]
- Fulop T, Larbi A, Witkowski JM, et al. Aging, frailty and age-related diseases. Biogerontology 2010;11(5):547-63
- NHS. Vaccine Choices. Available from: www.nhs.uk/chq/Pages/1039.aspx?CategoryID=62
- Vaccine choices for seniors. Available from: www.vaccines.gov/who_and_when/seniors/
- Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008;121(4):258-64
- Clements KM, Meier G, McGarry LJ, et al. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 2014;10:5
- Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003;21(16):1776-9
- Immunisation against infectious disease. The Green Book. Available from: www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
- Eichelberger M, Golding H, Hess M, et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development. Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008;26(34):4299-303
- Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35(1):69-75
- Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103(1-2):133-8
- Lang PO, Govind S, Mitchell WA, et al. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev 2011;10(3):389-95
- Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009;27(37):5043-53
- Remarque EJ, de Jong JM, van der Klis RJ, et al. Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol 1999;34(1):109-15
- Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198(5):650-8
- Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012;176(6):527-33
- Chen WH, Cross AS, Edelman R, et al. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011;29(16):2865-73
- Song JY, Cheong HJ, Noh JY, et al. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol 2013;85(9):1591-7
- Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27(52):7304-12
- Lavallee P, Perchaud V, Gautier-Bertrand M, et al. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002;33(2):513-18
- Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000;102(25):3039-45
- Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348(14):1322-32
- Assaad U, El-Masri I, Porhomayon J, El-Solh AA. Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 2012;7:453-61
- WHO. Recommendtions for the production and control of pneumococcal conjugate vaccines. Available from: www.who.int/entity/biologicals/publications/en/Pneumococcal%20Conjugate%20Vaccines_Recomm%20for%20the%20production%20&%20control%20of_ECBS%2054th%2017_21%20Nov%202003.pdf
- Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29(12):2287-95
- Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008;26(43):5521-6
- JCVI. Statement on the discontinuation of the routein pneumoccoal vaccination programme. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/jcvi/dh_094744
- JCVI. Updated statement on the routine pneumoccoal vaccination programme for adults aged 65 and over. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/jcvi/dh_094744 2011
- Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31(35):3577-84
- Musher DM, Manoff SB, McFetridge RD, et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011;7(9):919-28
- Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013;31(35):3585-93
- Lang PO, Michel JP. Herpes zoster vaccine: what are the potential benefits for the ageing and older adults? Eur Geriatr Med 2011;2:134-9
- van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27(9):1454-67
- Lang PO. Herpes zoster: the associated burden and its prevention. Geriatr Psychol Neuropsychiatr Vieil 2011;9(4):391-7
- Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 2012;24(4):494-500
- Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197(6):825-35
- Eilers R, Krabbe PF, van Essen TG, et al. Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr 2013;13:32
- NHS. Shingles Vaccination. Available from: www.nhs.uk/Conditions/vaccinations/Pages/shingles-vaccination.aspx
- Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011;29(20):3628-32
- Oxman MN, Levin MJ; Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008;197(Suppl 2):S228-36
- WHO. Tetanus. Available from: http://www.who.int/biologicals/vaccines/tetanus/en/
- WHO. Diptheria. Available from: http://www.who.int/biologicals/vaccines/diphtheria/en/
- WHO. Acellular Pertussis Vaccines. Available from: http://www.who.int/biologicals/areas/vaccines/apertussis/en/
- McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002;136(9):660-6
- CDC. Tetanus surveillance --- United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011;60(12):365-9
- van Panhuis WG, Grefenstette J, Jung SY, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med 2013;369(22):2152-8
- Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11(7):557-70
- McGarry LJ, Krishnarajah G, Hill G, et al. Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PloS One 2014;9(1):e72723
- Weinberger B, Schirmer M, Matteucci Gothe R, et al. Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons. PloS one 2013;8(12):e82967
- Ward JI, Cherry JD, Chang SJ, et al. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis 2006;43(2):151-7
- Van Damme P, McIntyre P, Grimprel E, et al. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix((R))) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 2011;29(35):5932-9
- Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. J Travel Med 2010;17(4):250-5
- Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006;6:130
- Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001;33(9):1553-66
- Looney RJ, Hasan MS, Coffin D, et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001;21(1):30-6
- Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PloS One 2011;6(12):e27753
- McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176(10):6333-9
- Hirokawa K, Utsuyama M, Ishikawa T, et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev 2009;130(1-2):86-91
- Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005;60(5):556-65
- Mitchell WA, Lang PO, Aspinall R. Tracing thymic output in older individuals. Clin Exp Immunol 2010;161(3):497-503
- Shen-Orr SS, Furman D. Variability in the immune system: of vaccine responses and immune states. Curr Opin Immunol 2013;25(4):542-7
- Furman D, Jojic V, Kidd B, et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013;9:659